- Home
- FFA vs SIGA Comparison
FFA vs SIGA Comparison
Compare FFA & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.26
Company Overview
Basic Information| Metric | FFA | SIGA |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.9M | 401.0M |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FFA | SIGA |
|---|---|---|
| Price | $21.09 | $5.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.5K | ★ 475.0K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | ★ 10.97% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | ★ N/A | $17.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.00 | $4.95 |
| 52 Week High | $22.31 | $9.62 |
Technical Indicators
Market Signals| Indicator | FFA | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 25.09 |
| Support Level | $20.84 | $5.21 |
| Resistance Level | $22.04 | $6.98 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 13.11 | 5.31 |
Price Performance
Historical Comparison FFA
SIGA
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.